Britton Boras

机构：Pfizer (United States) · ORCID：0000-0003-3624-9177

发表论文 42 篇 · 总被引 3394 次 · h-index 16

代表论文

• An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 (2021 · Science · 被引 1969)
• Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 (2021 · Nature Communications · 被引 297)
• Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans (2022 · Drug Metabolism and Disposition · 被引 120)
• A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 (2024 · Journal of Medicinal Chemistry · 被引 81)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 65)
• Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model (2024 · Science Advances · 被引 55)